Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for Drug Discovery at the 3rd Annual SABPA FTD Forum in San Diego, California, 2 of February.
Artificial Intelligence (AI) techniques, such as deep learning (DL) and reinforcement learning (RL) play a pivotal role in making the hunt for new pharmaceuticals quicker and more effective.The presentation will focus on the latest advances in artificial intelligence for discovery and development.
"We are happy to present our work at the 3rd Annual SABPA FTD Forum, which gathers the key industry leaders. The topic of AI for Drug Discovery is rapidly gaining popularity, and we are happy to be at the leading edge of research and one of the innovation drivers in the area", says Anne Tseng, Head of Business Development at Insilico Taiwan.
The 3rd Annual SABPA FTD Forum brings together key leaders of Gene, Cell Therapy and Artificial Intelligence industries. The speakers will share the latest breakthroughs and their visions in these areas. There will be several individual presentations and two-panel discussions focusing on CAR-T and AI, respectively. The audience will have great opportunities to ask questions, share ideas, learn from the experts, and network with their peers. The Forum is held on February 2nd, San Diego.
Alleo and Ubiquigent enter AI-driven strategic partnership to accelerate DUB-focused drug discovery